Terns Pharmaceuticals Inc (STU:430)
€ 5.6 0.05 (0.9%) Market Cap: 470.26 Mil Enterprise Value: 113.82 Mil PE Ratio: 0 PB Ratio: 1.34 GF Score: 39/100

Terns Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 06:40PM GMT
Release Date Price: €8.7 (+0.58%)
Jay Olson
Oppenheimer & Co. Inc. - Analyst

Hello, everyone, and welcome to Oppenheimer's 33rd Annual Healthcare Conference. I'm Jay Olson, one of the biotech analysts at Oppenheimer. And I want to thank you all for joining us here today. It's a pleasure to welcome Terns Pharmaceuticals to our conference, and it's an honor to introduce Erin Quirk, Head of R&D; and Mark Vignola, Chief Financial Officer. Thank you both so much for joining us today.

I'm going to turn it over to you for your presentation, and then I'll come back for some Q&A afterwards.

Erin Quirk
Terns Pharmaceuticals, Inc. - President, Head of Research & Development

Sounds great. So thank you, Jay and for the entire Oppenheimer team for the opportunity to present here today and tell you a little bit about the advancements we're making at Terns in serious metabolic and oncology diseases. I'd invite you to look to our website for our forward-looking statements and disclaimers as usual.

To provide an overview of turns on a one-pager, we are a publicly traded

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot